首页> 外文期刊>Anaesthesia and intensive care >Perioperative beta-blockade: guidelines and practice in New Zealand.
【24h】

Perioperative beta-blockade: guidelines and practice in New Zealand.

机译:围手术期β受体阻滞:新西兰的指南和实践。

获取原文
获取原文并翻译 | 示例
       

摘要

The aim of our study was to describe the knowledge and practice of New Zealand anaesthetists in relation to perioperative beta-adrenergic blockade, and to define barriers to implementation of perioperative beta-blockade in surgical patients at risk of myocardial ischaemia. A survey was sent to 400 New Zealand specialist anaesthetists. Information was sought on their knowledge and current practice relating to perioperative beta-blockade, and the barriers encountered to implementing therapy. The response rate was 59%. Perioperative beta-blockade was seen as beneficial in at risk patients by 95% of responding anaesthetists, but practice varied widely. Only 45% of anaesthetists always or usually commenced a beta blocker perioperatively, a department protocol was available to only 20%, and understanding of indications and contraindications to beta-blockade varied. There were logistical difficulties when initiating and monitoring perioperative beta-blocker regimens, and where treatment required multidisciplinary commitment. The lack of clarity of the guidelines was also a barrier to more widespread use. Difficulties were encountered relating general guidelines to individual patients, when co-morbidities, concurrent treatment and the influence of regional or general anaesthesia may influence the risk/benefit ratio. This study has identified variations in practice and reasons why New Zealand anaesthetists use of perioperative beta-blockers is at odds with published guidelines. Deficiencies in the guidelines are part of the problem. However, even with consensus on guidelines, effective multidisciplinary strategies will be required to optimize treatment of patients at risk of perioperative cardiac events.
机译:我们研究的目的是描述新西兰麻醉师有关围手术期β-肾上腺素能阻滞的知识和实践,并确定在有心肌缺血风险的手术患者中实施围手术期β-阻滞剂的障碍。已向400位新西兰专业麻醉师进行了调查。要求提供有关其有关围手术期β受体阻滞剂的知识和当前实践以及实施治疗遇到的障碍的信息。回应率为59%。 95%的有反应的麻醉师认为围手术期β受体阻滞对有风险的患者有益,但实践差异很大。只有45%的麻醉师总是或通常在围手术期开始使用β受体阻滞剂,只有20%的人可以使用部门协议,并且对β受体阻滞剂的适应症和禁忌症的理解也有所不同。在开始和监测围手术期β受体阻滞剂治疗方案以及需要多学科治疗的情况下,存在后勤方面的困难。准则缺乏明确性也是阻碍更广泛使用的障碍。当合并症,同时治疗以及区域或全身麻醉的影响可能影响风险/获益比时,遇到了与个别患者的一般指南相关的困难。这项研究发现了实践中的差异以及新西兰麻醉师围手术期使用β受体阻滞剂与已发布的指南不一致的原因。准则中的不足是问题的一部分。但是,即使就指南达成共识,仍需要有效的多学科策略来优化对有围手术期心脏事件风险的患者的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号